Anoro Ellipta Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Per pre-dispensed dose 62.5/25 mcg inhalation powd Umeclidinium 62.5 mcg, vilanterol trifenatate 25 mcg (delivered dose of umeclidinium 55 mcg, vilanterol trifenatate 22 mcg)

Indications/Uses

Maintenance bronchodilator treatment to relieve symptoms in adults w/ COPD.

Click to view Anoro Ellipta detailed prescribing information

Dosage/Direction for Use

1 inhalation once daily administered at the same time each day.

Click to view Anoro Ellipta detailed prescribing information

Overdosage

View Anoro Ellipta overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity to umeclidinium, vilanterol trifenatate, lactose monohydrate & Mg stearate.

Click to view Anoro Ellipta detailed prescribing information

Special Precautions

Not to be used in asthma, acute bronchospasm, severe heart disease, glaucoma, urinary retention. COPD worsening, diabetes, hypokalaemia, hyperglycaemia, seizures, thyroid disorders or sensitivity to β₂-agonists. Monitor during concomitant use w/ drugs lowering K. Avoid use in patients w/ galactose intolerance. Not to be used in severe liver impairment. Monitor use during pregnancy & lactation. Not to be used in childn <18 yr.

Click to view Anoro Ellipta detailed prescribing information

Use In Pregnancy & Lactation

Click to view Anoro Ellipta detailed prescribing information

Adverse Reactions

UTI, sinusitis, nasopharyngitis, pharyngitis, URTI; cough, oropharyngeal pain; constipation, dry mouth.

Click to view Anoro Ellipta detailed prescribing information

Drug Interactions

Weakened or antagonised effect by β-adrenergic blockers. Increased systemic exposure w/ strong CYP3A4 inhibitors eg, ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin. Potentiated adverse reaction w/ other antimuscarinics & sympathomimetics. Potentiated hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics.

Click to view Anoro Ellipta detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Anoro Ellipta detailed prescribing information

Storage

View Anoro Ellipta storage conditions for details to ensure optimal shelf-life.

Description

View Anoro Ellipta description for details of the chemical structure and excipients (inactive components).

Action

View Anoro Ellipta mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03AL03 - vilanterol and umeclidinium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.

Regulatory Classification

Presentation/Packing

Form

Anoro Ellipta 62.5/25 mcg inhalation powd

Packing/Price

30's

Anoro Ellipta

umeclidinium + vilanterol

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma